A Study to Determine the Effect of CYP3A Inhibition on the Pharmacokinetics of LY2623091 and the Effect of LY2623091 on the Pharmacokinetics of CYP3A Substrates in Healthy Subjects

Trial Profile

A Study to Determine the Effect of CYP3A Inhibition on the Pharmacokinetics of LY2623091 and the Effect of LY2623091 on the Pharmacokinetics of CYP3A Substrates in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Mar 2016

At a glance

  • Drugs LY 2623091 (Primary) ; Diltiazem; Itraconazole; Simvastatin; Tadalafil
  • Indications Essential hypertension
  • Focus Pharmacokinetics
  • Sponsors Eli Lilly
  • Most Recent Events

    • 12 Mar 2016 Pharmacokinetic results (n=32) of LY-2623091 with itraconazole and diltiazem were presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 16 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 11 Mar 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top